---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: REVEAL pivotal"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: REVEAL pivotal. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 57 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence/reveal-pivotal"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: REVEAL pivotal

<a id="heading-3.1.1"></a>

## 3.1.1 REVEAL Pivotal

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Registered objectives of NCT05606614

> “The primary objectives of this study are to evaluate the safety of a single intrathecal (IT) dose of TSHA-102 in females with typical Rett syndrome, to select the TSHA-102 dose with the best benefit/risk profile based on the totality of safety and efficacy data and to evaluate the efficacy and safety of TSHA-102 at the selected dose.”
> “REVEAL Part B (Phase 3) will evaluate the efficacy and safety of TSHA-102 at the dose level 2 determined in Part A in 15 females ages 6 to <22 years with typical Rett syndrome.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.1-2"></a>

#### Role of the pivotal trial in the development plan

> “The TSHA-102 clinical development program is designed to support the potential future approval of TSHA-102 for a broad population of patients aged 2 years and older with Rett syndrome through an efficient and rigorously designed pathway.”
> “In close collaboration with the FDA we designed the TSHA-102 pivotal program so that efficacy data from the REVEAL pivotal trial in patients aged 6 to <22 years who have reached developmental plateau can be used to represent patients aged 2 to <6 years, while safety data in younger children are generated through the separate ASPIRE trial to support the potential for a broad label for TSHA-102.”
> “Developmental milestones are defined as a functional gain of one or more of the 28 milestones defined in the natural history study. This is the primary evidence of efficacy that will support our planned BLA submission and the FDA’s review of efficacy in the REVEAL pivotal trial.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Country of the pivotal trial

> “The trial is taking place in the United States.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.2-2"></a>

#### Registered sites for NCT05606614 (Parts A and B combined)

| Site | Registry record |
| --- | --- |
| Duarte, California, United States | “City of Hope” |
| La Jolla, California, United States | “UC San Diego” |
| Oakland, California, United States | “UC San Francisco Benioff Children's Hospital” |
| Chicago, Illinois, United States | “Rush University Medical Center” |
| Baltimore, Maryland, United States | “Kennedy Krieger Institute” |
| Boston, Massachusetts, United States | “Boston Children's Hospital” |
| St Louis, Missouri, United States | “Washington University, St. Louis” |
| Dallas, Texas, United States | “UT Southwestern Children's Medical Center” |
| Montreal, Quebec, Canada | “CHU St. Justine” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.2-3"></a>

#### Site activation after regulatory feedback

> “Taysha commenced site activation for the REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of a NOL from Health Canada and written feedback from the FDA”

Source: [Taysha Gene Therapies second quarter 2025 results announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/d51118dex991.htm)

<a id="topic-3.1.1.2-4"></a>

#### First participant dosed

> “In December 2025, the Company dosed the first patient with TSHA-102 in the Phase 1/2 Part B REVEAL pivotal trial and therefore triggered a milestone payment in connection with the Abeona Rett Agreement.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.2-5"></a>

#### Completion of dosing

> “Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6-month interim”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="topic-3.1.1.2-6"></a>

#### Anticipated interim data

> “Topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 expected in the first half of 2027”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Single-arm, open-label design with participants as their own control

> “The REVEAL pivotal trial, also known as Part B, is a single-arm, open-label study evaluating the efficacy and safety of high dose TSHA-102 as a single lumbar intrathecal administration in females aged 6 to <22 years with Rett syndrome due to MECP2 loss-of-function mutation, with each patient serving as their own control.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.3-2"></a>

#### Registry design: phase 1/2/3 record with outcome assessor masking

> “An Open-label Phase 1/2/3 Study Consisting of a Phase 1/2 Safety and Dose-escalation and Phase 3 Dose-expansion Study to Evaluate Safety and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy in Females With Rett Syndrome”
> “Central raters assessing the gain or regain of a developmental milestone from videos are blinded to the timing of each video.”
> “Each participant will be followed for the observation period of 5 years after TSHA-102 administration in Part A and B.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.3-3"></a>

#### FDA written alignment on key design elements

> “Written alignment from FDA supports single-arm, open label pivotal trial with primary endpoint of developmental milestone gain/regain in the developmental plateau population (≥ 6 years, intend N=15) with each patient serving as their own control”
> “12-month primary analysis, and intend to perform a 6-month interim analysis”
> “The FDA advised the Company to submit the pivotal Part B trial protocol and the associated SAP as an amendment to its IND application, eliminating the need for formal end-of-phase meeting”

Source: [Taysha Gene Therapies pivotal trial design announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525129494/d904503dex991.htm)

<a id="topic-3.1.1.3-4"></a>

#### Finalized protocol and statistical analysis plan with a 6-month interim analysis

> “Additionally, the Company announced that it has finalized alignment with the FDA on the REVEAL pivotal trial protocol and statistical analysis plan (SAP) that are intended to support the planned Biologics License Application (BLA) submission for TSHA-102, following the resolution of remaining clinical and statistical queries.”
> “Inclusion of a 6-month interim analysis that may serve as the basis for BLA submission: enabled by the rigorous, objective evaluation criteria used to evaluate developmental milestone achievement in Part A of the REVEAL Phase 1/2 trials and the unprecedented 83% response rate seen at six months following high dose TSHA-102 (5 out of 6 patients; May 2025 data cutoff) in Part A that deepened over time”

Source: [Taysha Gene Therapies Breakthrough Therapy designation announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525227505/d61846dex991.htm)

<a id="topic-3.1.1.3-5"></a>

#### Natural history external reference: Rett Syndrome Natural History Study

> “The purpose of this study is to advance understanding of the natural history of Rett syndrome (RTT), MECP2-duplication disorder (MECP2 Dup), CDKL5, FOXG1, and individuals with MECP2 mutations who do not have RTT including the range of clinical involvement and to correlate genotype-phenotype over a broad spectrum of phenotypes.”
> “This study will not include clinical trials, but should set the stage for such trials and other translational research projects (e.g., development of biomarkers).”

Source: [ClinicalTrials.gov NCT02738281](https://clinicaltrials.gov/study/NCT02738281)

<a id="topic-3.1.1.3-6"></a>

#### Natural history external reference: trial-aligned analysis cohort and simulated control cohorts

> “The RNHS dataset comprises 1870 individuals.”
> “1191 (63.7%) participants were included, with a mean (SD) age at first study visit of 10.2 (9.3) years (Table 1)”
> “Participants were female with typical RTT and confirmed MECP2 mutation; inclusion/exclusion criteria were aligned to those typically used in interventional RTT trials”
> “Using RNHS participants in the developmental plateau (age ≥6 years) cohort, bootstrap simulations (10,000 iterations) were used to generate trial-like untreated cohorts (N=15; 1-year follow-up) via repeated sampling of the RNHS analysis cohort under prespecified assumptions”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.3-7"></a>

#### Reasons given for not using a concurrent control

> “Trial design challenges are compounded when evaluating an investigational gene therapy for RTT due to ethical and methodological concerns with sham controls (e.g., lumbar puncture without active agent), potential functional unblinding from required immunosuppression, and delayed-treatment control designs that may expose participants to unjust harm by postponing intervention during critical neurodevelopmental windows”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.3-8"></a>

#### FDA draft guidance on single-arm trials using participants as their own control

> “This design leverages an internal, baseline control strategy where a participant’s response to therapy on a given measure is compared to their baseline status on that measure.”
> “Self-controlled studies can be particularly persuasive when a condition is universally degenerative in all affected individuals, and the intervention is expected to lead to improvement.”
> “Finally, the selection of objectively measured endpoints that are not effort-dependent is critical to interpreting results from self-controlled or other non-blinded trials.”

Source: [FDA Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations draft guidance (2025)](https://www.fda.gov/media/188892/download)

<a id="topic-3.1.1.3-9"></a>

#### Blinded central rating of pre- and post-treatment videos

> “Pre- and post-treatment videos are evaluated by centralized, blinded raters using a standardized process to ensure consistent, objective evaluations of prespecified milestone demonstrations.”
> “Raters are highly trained clinical psychologists/physical therapists with experience in RTT.”
> “Bias Mitigation Strategy: Blinded central rating includes pre- and post-treatment videos in each package.”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Registered inclusion and exclusion criteria

| Criterion | Registry record |
| --- | --- |
| Age and sex (inclusion) | “females between the ages of 6 and <22 in Part B (pivotal cohort).” |
| Diagnosis (inclusion) | “Participant has a clinical diagnosis of classic/typical Rett syndrome with a documented pathogenic mutation of the methyl-CpG-binding protein 2 (MECP2) gene that results in loss of gene function.” |
| Blood products (inclusion) | “Participants must be willing to receive blood or blood products for the treatment of an AE if medically needed.” |
| Residence near the site (inclusion) | “Participants and parent/caregiver must agree to reside within easy access to the study site prior to the baseline visit and at least 3 months after TSHA-102 treatment” |
| Other neurodevelopmental disorder (exclusion) | “Participant has another neurodevelopmental disorder independent of the MECP2 loss-of-function mutation, or any other genetic syndrome with a progressive course.” |
| Brain injury or early abnormal development (exclusion) | “Participant has a history of brain injury that causes neurological problems or had grossly abnormal psychomotor development in the first 6 months of life.” |
| Atypical Rett syndrome (exclusion) | “Participant has a diagnosis of atypical Rett syndrome or a MECP2 gene mutation that does not cause Rett syndrome.” |
| Ventilation (exclusion) | “Participant requires invasive ventilatory support.” |
| Additional criteria | “Other protocol defined inclusion/exclusion criteria may apply” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.4-2"></a>

#### Developmental plateau population aged 6 years and older

> “The study enrolled females in the developmental plateau population of Rett syndrome; these patients have an exceedingly low likelihood (0% to <6.7%) of gaining new or regaining developmental milestones that were lost after a defined number of years, based on our analysis of the National Institutes of Health, or NIH, -funded International Rett Syndrome Foundation’s natural history study data.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.4-3"></a>

#### Rationale for the minimum age of 6 years

> “Before 6 years of age, milestone gain, loss, and regain were more variable and less predictable, with spontaneous first-time gain for a single milestone as high as 97%; inclusion of younger participants without explicit age accounting could increase background spontaneous gain and thereby increase type I error”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.4-4"></a>

#### Milestone-level eligibility at screening and baseline

> “Criteria required for a milestone to be considered eligible for gain/regain”
> “Medical history confirmation the milestone was either never achieved or lost sufficiently long ago”
> “In-clinic video assessment confirmation milestone was not demonstrated”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Registered intervention and arm

> “TSHA-102 at Selected Dose (Dose Level 2): 1.0 × 10¹⁵ total vector genomes (vg)”
> “Participants receive a single intrathecal (IT) administration of TSHA-102 at Dose Level 2 (1.0 × 10¹⁵) (fully enrolled, 17 participants).”
> “TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.5-2"></a>

#### Single lumbar intrathecal administration of the high dose

> “Each participant will receive a single administration of the high dose (1x1015 total vg) of TSHA-102 delivered by lumbar intrathecal injection.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-3.1.1.5-3"></a>

#### Dose selection from Part A

> “The maximum tolerated dose, or MTD, or maximum administered dose, or MAD, established in Part A will be administered during dose expansion in Part B, which is the pivotal phase of the trials.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Rett Syndrome Developmental Milestone Assessment Response as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Registered primary outcome of Part B

| Outcome | Registry record | Time frame |
| --- | --- | --- |
| Primary (Part B) | “Change from baseline in percentage of participants who gain or regain any one or more of the 28 items from the Developmental Milestones Assessment (DMA), which are video recorded and scored by independent, blinded central raters.” | “Baseline through Week 52” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.1.6.1-2"></a>

##### Primary endpoint definition and key secondary endpoints

> “The primary endpoint will assess response rate, defined as the percentage of patients who gain or regain at least one developmental milestone from a list of 28 natural-history defined milestones across the core functional domains of communication, fine motor and gross motor, following administration of TSHA-102.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

> “Key secondary endpoints in the REVEAL pivotal trial include the average number of total developmental milestones gained or regained per patient following TSHA-102, as well as clinician-assessed outcome measures, including the R-MBA and CGI-I.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-3.1.1.6.1-3"></a>

##### The 28 developmental milestones

| Domain | Milestones |
| --- | --- |
| Gross motor | “Come to sitting”; “Sat without support”; “Stood while holding on”; “Pulled to standing”; “Stood independently”; “Walked with support”; “Walked independently”; “Climbed up stairs with help”; “Climbed down stairs with help”; “Climbed up stairs without help”; “Climbed down stairs without help”; “Ran 10 feet without falling” |
| Fine motor | “Reached for toy”; “Holds bottle unpropped”; “Used raking grasp to retrieve an object”; “Used pincer grasp (refined or modified)”; “Transferred an object from one hand to another”; “Finger feed”; “Drank from a cup held without assistance”; “Used a fork or spoon to eat with assistance”; “Used a fork or spoon to eat without assistance” |
| Communication | “Pointed for something they wanted”; “Followed a command with a gesture”; “Identified body parts (pointed with eyes or fingers)”; “Followed a command without a gesture”; “Used word(s) with meaning”; “Spoke in phrases (2 words or more) with meaning” |

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.6.1-4"></a>

##### Selection of the 28 milestones from the natural history study

> “Starting from 51 potential developmental milestones captured in the RNHS protocols (#5201, 2006–2014; #5211, 2015–2021)”
> “RNHS study principal investigators, RTT specialists, and caregivers identified milestones that were linked to activities of daily living and that were independently meaningful based on caregiver concept elicitation work”
> “Finally, milestones with higher likelihood of spontaneous gain in an untreated population were also excluded, resulting in a selected set of 28 milestones for analysis (Figure 1)”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.6.1-5"></a>

##### Natural history: developmental plateau after 6 years of age in the Taysha-funded analysis

> “A clear developmental plateau emerged in children aged ≥6 years, after which spontaneous gain, and regain after sustained loss, was rare (first time gain <3% across milestones; Figure 3A; regain shown in Figure 3C)”
> “Time-since-loss parameters were important for interpretation of milestone regain because spontaneous regain likelihood varied as a function of time since milestone loss”
> “No consistent significant predictors of gain/regain were identified across the 28 milestones, such as”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.6.1-6"></a>

##### Natural history: skill gain, loss, and regain in 1228 females with classic Rett syndrome

> “The occurrence and time of gain, loss, and regain of 51 developmental skills was collected during in-person visits in the RTT Natural History Study from 1228 females with Classic RTT and a pathogenic loss-of-function variant in MECP2.”
> “Regain of lost skills was infrequent for most skills, occurred mainly before 6 years old, and within 2 years of loss. After 6 years old, the incidence of either gaining or regaining skills was low.”
> “The lack of gain or regain of skills beyond 6 years old suggest that any functional gains in these skills after a clinical intervention would represent an important indicator of efficacy as a clinical trial endpoint in RTT.”
> “In this restricted set of developmental skills, the percentage of participants who gained at least one of these 38 skills fell below 5% per year after 6 years of life.”

Source: [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/)

<a id="topic-3.1.1.6.1-7"></a>

##### Natural history: advantages of developmental endpoints in trials that cannot be double-blind

> “This is especially critical for clinical trials that preclude conducting studies in a double-blind fashion.”
> “The advantages of these developmental endpoints are: (1) they are easily defined, (2) binary, and (3) likely to be emergent with an effective treatment paradigm.”
> “trials to define the expected trajectory and likelihood of gain or regain in an untreated cohort as a comparator to participants in an open label trial.”

Source: [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/)

<a id="topic-3.1.1.6.1-8"></a>

##### Natural history: earlier analysis of developmental skills

> “Early developmental skills were acquired by many, but clear differences from normal emerged, particularly in skills expected after age 6 months.”
> “These data may serve for planning and interpretation of early intervention studies in RTT.”

Source: [Neul et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4112822/)

<a id="topic-3.1.1.6.1-9"></a>

##### Psychometric validation of the RS-DMA in the RESUME study

> “The RESUME study is a U.S. based, non-interventional, and multisite longitudinal study designed to establish trial-ready video-capture and assessment methodologies in RTT”
> “Thirteen participants (N=13; Age: M=11.3, SD=4.7; CGI-S: M=4.9, SD=0.9) completed the RS-DMA, alongside other assessments, to evaluate the psychometrics and trial-readiness”
> “The RS-DMA met reliability criteria, as overall reliability of the RS-DMA was excellent across all items and raters (Fleiss Kappa= 0.82, 92.9% agreement, PABAK= 0.86)”
> “The RS-DMA met feasibility criteria, with a mean feasibility score of 8.27 (SD=1.17), indicating 83% of RS-DMA video recordings were deemed feasible for central rating”
> “The RS-DMA met fidelity criteria, with a mean score of 85.8% (SD=3.30%).”
> “100% of the 28 milestones were endorsed by a majority of caregivers as independently meaningful as a potential treatment response, after observing the RS-DMA”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="topic-3.1.1.6.1-10"></a>

##### RS-DMA milestone with lower rater agreement: identifies body parts

> “Substantial to excellent agreement among central raters for 27 of the 28 individual RS-DMA milestones, and a fair level of agreement for the milestone”
> “Identifies body parts,”
> “due to challenges with feasibility when the eye-tracking overlay was not available (Table 1; Figure 3B)”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="topic-3.1.1.6.1-11"></a>

##### RS-DMA historical caregiver interview compared with performative assessment

> “There was a range of Slight to Excellent agreement between the RS-DMA Historical Caregiver Interview vs performative RS-DMA with an average of 81.8% and more than a third of items rating at Slight or Fair”
> “Standardized in-clinic administration may result in type 2 errors (false negatives), which for truly disease modifying treatments is an acceptable potential signal loss in favor of controlling for type 1 errors (false positives)”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="topic-3.1.1.6.1-12"></a>

##### Limitations of existing Rett syndrome outcome assessments for single-arm designs

> “Existing Clinical Outcome Assessments (COAs) in RTT are not well-suited as primary endpoints in single-arm designs using a PABA analysis framework”
> “as they cannot be bias-mitigated through blinded video review, lack a natural history anchored plateau, or rely on summary scores that lack sensitivity to individualized change”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="topic-3.1.1.6.1-13"></a>

##### FDA interactions on the responder definition and the assessment

> “During advanced discussions with the FDA, reached alignment on the definition of a responder:”
> “gain/regain of ≥ one defined developmental milestone.”
> “The FDA provided guidance on an additional analysis to further support the responder definition, which the Company has completed and intends to submit, alongside the final protocol and statistical analysis plan (SAP), as part of the Investigational New Drug (IND) amendment.”

Source: [Taysha Gene Therapies pivotal trial design announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525129494/d904503dex991.htm)

> “The RS-DMA has been developed through multiple interactions with FDA who commented on”
> “the thoughtful approach taken in designing the Developmental Milestone Assessment (DMA) tool”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="topic-3.1.1.6.1-14"></a>

##### Caregiver views on meaningful milestone gains

> “A total of 22 U.S.-based caregivers of individuals with classic Rett syndrome (aged 5–39 years) participated (Figure 1)”
> “Caregivers valued gain/regain of developmental milestones from gene therapy”
> “This data informed the use of the Developmental Milestone Assessment in a gene therapy clinical trial (REVEAL)”

Source: [Keeley et al. (2025)](https://tayshagtx.com/wp-content/uploads/Every-Gain-Expanding-Possibilities-Caregiver-Insights-on-Meaningful-Improvement-in-Rett-Syndrome-Gene-Therapy-GT.pdf)

<a id="topic-3.1.1.6.1-15"></a>

##### Key secondary endpoint instrument: Revised Motor Behavior Assessment

> “Using data from a natural history study (n = 1,075), we examined the factor structure, internal consistency, and validity of the clinician-reported Motor Behavior Assessment scale (MBA).”
> “The analysis resulted in a five-factor model: (1) motor dysfunction, (2) functional skills, (3) social skills, (4) aberrant behavior, and (5) respiratory behaviors.”
> “Further work is needed to evaluate this measure longitudinally and to add items related to the RTT phenotype.”

Source: [Raspa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7778880/)

<a id="topic-3.1.1.6.1-16"></a>

##### Key secondary endpoint instrument: Clinical Global Impression scales with Rett-specific anchors

> “Despite its favorable assay sensitivity in clinical trials, as a global measure, the Clinical Global Impression Scale is not specific to the signs and symptoms of the disorder under study.”
> “Development of key anchors for the scale, specific to the disorder being assessed, holds promise for enhancing the validity and reliability of the measure for disorders such as Rett syndrome.”

Source: [Neul et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4610825/)

<a id="topic-3.1.1.6.1-17"></a>

##### Validation status of Rett syndrome outcome measures

> “Reliability, validity, and responsiveness profiles were mostly incomplete; there were limited content validation data, particularly parent-informed relevance, comprehensiveness and comprehensibility of items; and no data on meaningful change or cross-cultural validity.”
> “Validity data are not available although evidence of responsiveness was suggested in the paediatric Phase 2 [39] and 3 [14] trofinetide trials.”

Source: [Downs et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11663341/)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment

> “The REVEAL pivotal trial is a single-arm, open-label trial that will enroll 15 females aged 6 to <22 years who are in the developmental plateau population of Rett syndrome.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-3.1.1.7.1-2"></a>

##### Sample size and power

> “Power analyses and bootstrap simulations supported a conservative natural-history-informed null threshold of 6.7% at a feasible sample size of N=15 under modeled trial-like sampling assumptions for aggregate responder analyses using milestone gain or regain”
> “Table 2: Power calculation indicates that a minimum of five responders would be required to reject the natural-history-informed null hypothesis with a sample size of 15”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.7.1-3"></a>

##### Overenrollment to 17 participants

> “We have completed dosing of the 17 patients aged 6 to <22 years in the overenrolled REVEAL pivotal trial, and enrollment for this trial is complete with a well-balanced age distribution across all pediatric, adolescent and adult patients dosed.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.7.1-4"></a>

##### Participants to be analyzed at the interim analysis

> “The interim analysis to support the planned Biologics License Application (BLA) submission is expected to occur after all 17 patients complete six months of post-treatment follow-up.”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Null hypothesis and success threshold

> “A response rate of 33% (5 out of 15 patients) is the minimum threshold for success sufficient to reject the null hypothesis. Based on our natural history data analysis, the null hypothesis is that one out of 15 patients aged ≥ 6 years may gain/regain one of the 28 natural history defined developmental milestone without treatment, corresponding to a response rate of 6.7%.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

> “The response rate of 33% is the minimum threshold for success sufficient to reject the natural history established null hypothesis of 6.7%.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.7.2-2"></a>

##### Derivation of the 6.7% null threshold

> “The highest observed spontaneous gain rate after age 6 years was 3% which, at N=15, corresponded to 0.45 expected spontaneous responders; however, as responder rate must be discrete, one spontaneous responder (6.7%) was selected as the null threshold and evaluated across feasible sample sizes and responder counts using power calculations”
> “Across 10,000 simulations (N=15; ≥6 years of age), only 1.8% of simulations had ≥2 responders (Table 3)”
> “Across 150,000 simulated participants, this equated to a spontaneous responder rate of 1.39%”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.7.2-3"></a>

##### Plateau-anchored, baseline-adjusted aggregate responder analysis

> “RNHS cumulative incidence estimates were used to construct the PABA aggregate responder framework by defining milestone eligibility and deriving a conservative natural-history-informed null threshold.”
> “Each milestone was assessed to determine the minimum time-since-loss at which spontaneous regain falls below the defined null threshold”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-3.1.1.7.2-4"></a>

##### Primary analysis, interim analysis, and rater allocation by time point

> “SAP: 33% response rate is the minimum threshold for success sufficient to reject the null hypothesis of 6.7%”
> “12-month primary analysis FDA alignment on potential to submit BLA based on 6-month interim analysis”

Source: [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)

> “Figure 5: DMA implementation process in the REVEAL pivotal trial”
> “Raters will not see the same participant's videos back-to-back and will have maximum spacing to prevent direct comparisons.”

Source: [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Participants dosed

> “Completed dosing in the overenrolled REVEAL pivotal trial, with a total of 17 females in the developmental plateau population of Rett syndrome dosed with TSHA-102”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="topic-3.1.1.8.1-2"></a>

##### Acute post-dosing safety monitoring period completed

> “All patients in the REVEAL Phase 1/2 (n=12), pivotal (n=17) and ASPIRE (n=4) trials have cleared the acute post-dosing safety monitoring period typically associated with AAV gene therapies with no dose-limiting toxicities observed across all trials.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Age distribution of dosed participants

> “We have completed dosing of the 17 patients aged 6 to <22 years in the overenrolled REVEAL pivotal trial, and enrollment for this trial is complete with a well-balanced age distribution across all pediatric, adolescent and adult patients dosed.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Treatment-related serious adverse event: peripheral sensory neuropathy

> “In July 2026, one patient in the REVEAL pivotal trial experienced a single, moderate Grade 2 technical classification of a treatment-related event of peripheral sensory neuropathy, an expected AAV-associated risk, approximately six weeks post-TSHA-102.”
> “In accordance with the treating institution’s protocol, the patient was admitted overnight for management and observation, thus, resulting in the technical classification of the Grade 2 event as an SAE.”
> “The patient was discharged the following day, and importantly, rapidly demonstrated substantial recovery. The patient has demonstrated continued meaningful improvement over the last three months and is almost back to baseline.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.1.8.5-2"></a>

##### Pooled safety across the REVEAL Phase 1/2, REVEAL pivotal, and ASPIRE trials: November 2026 cutoff

> “High dose (1x1015 total vector genomes (vg)) and low dose (5.7x1014 total vg) TSHA-102 continue to be generally well tolerated with no severe treatment-related serious adverse events (SAEs) or dose limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-3.1.1.8.5-3"></a>

##### Pivotal trial safety: June 2026 cutoff

> “TSHA-102 continues to be generally well tolerated, with no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) reported as of the June 2026 data cutoff”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="topic-3.1.1.8.5-4"></a>

##### Pivotal trial safety: March 2026 cutoff

> “There have been no treatment-related serious adverse events or dose-limiting toxicities across the participants treated with TSHA-102 in the REVEAL pivotal trial as of the March 2026 data cutoff.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

- Design and comparator: REVEAL Pivotal is a single-arm, open-label trial with no concurrent control. Efficacy is judged against an external null response rate of 6.7% (1 of 15 participants) derived from the Rett Syndrome Natural History Study, with a 33% response rate (5 of 15) as the minimum threshold for success. The natural history analysis cites sham lumbar puncture, functional unblinding from required immunosuppression, and delayed treatment as ethical and methodological obstacles to a controlled design.
- Derivation of the null: the 28 milestones, the minimum age of 6 years, the time-since-loss rules, and the 6.7% threshold come from analyses of Rett Syndrome Natural History Study data. The highest spontaneous gain rate observed after 6 years of age was 3%, corresponding to 0.45 expected spontaneous responders among 15 participants, and one spontaneous responder (6.7%) was selected as the null threshold because the responder count must be discrete.
- Baseline and milestone eligibility: a milestone is eligible for gain or regain when medical history confirms that it was never achieved or was lost sufficiently long ago and an in-clinic video assessment confirms that it is not demonstrated. In the RESUME validation study, agreement between the RS-DMA historical caregiver interview and the performative RS-DMA averaged 81.8%, with more than one-third of items at slight or fair agreement.
- Endpoint validation: the RS-DMA was validated in a non-interventional study of 13 participants. Inter-rater agreement was substantial to excellent for 27 of the 28 milestones and fair for identifying body parts, and 83% of video recordings were rated feasible for central rating. A responder is a participant who gains or regains at least 1 of 28 milestones, so a single milestone of any type meets the definition.
- Blinding and assessment: only central raters are masked, and only to the timing of each video. Milestone demonstration is a performed task administered in clinic. The 2025 FDA draft guidance states that self-controlled studies can be particularly persuasive when a condition is universally degenerative in all affected individuals and the intervention is expected to lead to improvement, and that objectively measured endpoints that are not effort-dependent are critical to interpreting self-controlled or other non-blinded trials. The natural history data describe a developmental plateau from 6 years of age and slow loss of gross motor skills during Stage III.
- Secondary endpoints: the key secondary measures are the R-MBA and CGI-I. One publication describes the reliability, validity, and responsiveness profiles of the outcome measures it assessed as mostly incomplete, with no data on meaningful change, and the psychometric study of the clinician-reported MBA called for longitudinal evaluation of the measure.
- Size, timing, and analysis: 17 females aged 6 to under 22 years were dosed against a planned 15. A BLA may rest on a 6-month interim analysis, while the registered primary outcome runs from baseline through week 52 and the statistical analysis plan names a 12-month primary analysis. The registered primary outcome is worded as a change from baseline in the percentage of responders, which differs from the response rate the sponsor describes. No published protocol or statistical analysis plan was identified.
- Population and extrapolation: eligibility is limited to females with classic Rett syndrome and a loss-of-function MECP2 variant, excluding atypical Rett syndrome and participants needing invasive ventilation. The sponsor plans to extrapolate efficacy to children aged 2 to under 6 years, an age range in which the natural history analysis reports spontaneous first-time gain of a single milestone as high as 97%.
- Results and safety reporting: no efficacy results have been reported; topline interim data are expected in the first half of 2027. Safety has been reported in company filings and press releases, mostly pooled with the phase 1/2 and ASPIRE trials (33 participants). One pivotal participant had a treatment-related Grade 2 serious adverse event of peripheral sensory neuropathy about 6 weeks after dosing in July 2026; no adverse event table specific to the pivotal trial was identified.
- Reporting consistency: the third quarter 2026 Form 10-Q states that the pivotal trial is taking place in the United States, while the combined registry record lists a site in Montreal and the sponsor reported a No Objection Letter from Health Canada before site activation.

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm); [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm); [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm); [Taysha Gene Therapies second quarter 2025 results announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/d51118dex991.htm); [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf); [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf); [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/); [FDA Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations draft guidance (2025)](https://www.fda.gov/media/188892/download); [Downs et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11663341/); [Raspa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7778880/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
